The symbol of Biogen Pharmachem Industries Ltd is ... Regime for more savings in new financial year? Not Titan, this is stock is at the top of Jhunjhunwala's portfolio; check details 'Even ...

Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Hedge funds have recently bought and sold shares of the stock. Lee Danner & Bass Inc. purchased a new stake in shares of Biogen in the fourth quarter valued at $25,000. Larson Financial Group LLC ...

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

The stock's fall snapped a seven-day winning streak.

In the past year, the stock has declined 36.6% compared with the industry’s 8.5% decline. Biogen is developing felzartamab across a range of immune-mediated diseases and believes the candidate ...

Felzartamab is still an investigational drug that has not yet received regulatory approval, which poses a risk for investors and stakeholders regarding its eventual market success. The need for a ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...